Cargando…

Combining liquid biopsy and functional imaging analysis in metastatic castration‐resistant prostate cancer helps predict treatment outcome

Plasma tumour DNA (ptDNA) is a potential early noninvasive biomarker of treatment outcome in metastatic castration‐resistant prostate cancer (mCRPC). Herein, we investigated whether pretreatment ptDNA levels reflect metabolic tumour burden in mCRPC and better predict treatment outcome in combination...

Descripción completa

Detalles Bibliográficos
Autores principales:	Conteduca, Vincenza, Scarpi, Emanuela, Caroli, Paola, Lolli, Cristian, Gurioli, Giorgia, Brighi, Nicole, Poti, Giulia, Farolfi, Alberto, Altavilla, Amelia, Schepisi, Giuseppe, Matteucci, Federica, Paganelli, Giovanni, De Giorgi, Ugo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8763654/ https://www.ncbi.nlm.nih.gov/pubmed/34657387 http://dx.doi.org/10.1002/1878-0261.13120

Ejemplares similares

Baseline Plasma Tumor DNA (ctDNA) Correlates with PSA Kinetics in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide
por: Conteduca, Vincenza, et al.
Publicado: (2022)

Plasma AR Copy Number Changes and Outcome to Abiraterone and Enzalutamide
por: Gurioli, Giorgia, et al.
Publicado: (2020)

Melphalan as a Promising Treatment for BRCA-Related Ovarian Carcinoma
por: Conteduca, Vincenza, et al.
Publicado: (2021)

Flare phenomenon in prostate cancer: recent evidence on new drugs and next generation imaging
por: Conteduca, Vincenza, et al.
Publicado: (2021)

Immunotherapy and Its Development for Gynecological (Ovarian, Endometrial and Cervical) Tumors: From Immune Checkpoint Inhibitors to Chimeric Antigen Receptor (CAR)-T Cell Therapy
por: Schepisi, Giuseppe, et al.
Publicado: (2021)

The Interplay between Inflammation, Anti-Angiogenic Agents, and Immune Checkpoint Inhibitors: Perspectives for Renal Cell Cancer Treatment
por: Brighi, Nicole, et al.
Publicado: (2019)

Circulating tumor cell gene expression and plasma AR gene copy number as biomarkers for castration-resistant prostate cancer patients treated with cabazitaxel
por: Gurioli, Giorgia, et al.
Publicado: (2022)

Plasma tumour DNA as an early indicator of treatment response in metastatic castration-resistant prostate cancer
por: Conteduca, Vincenza, et al.
Publicado: (2020)

Circulating AR copy number and outcome to enzalutamide in docetaxel-treated metastatic castration-resistant prostate cancer
por: Salvi, Samanta, et al.
Publicado: (2016)

Circulating androgen receptor combined with 18F-fluorocholine PET/CT metabolic activity and outcome to androgen receptor signalling-directed therapies in castration-resistant prostate cancer
por: Conteduca, V., et al.
Publicado: (2017)

Potential Application of Chimeric Antigen Receptor (CAR)-T Cell Therapy in Renal Cell Tumors
por: Schepisi, Giuseppe, et al.
Publicado: (2020)

Plasma Androgen Receptor in Prostate Cancer
por: Conteduca, Vincenza, et al.
Publicado: (2019)

Plasma androgen receptor and serum chromogranin A in advanced prostate cancer
por: Conteduca, Vincenza, et al.
Publicado: (2018)

Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer
por: Conteduca, Vincenza, et al.
Publicado: (2018)

Vitamin D status among long-term survivors of testicular cancer
por: Schepisi, Giuseppe, et al.
Publicado: (2016)

Early outcome prediction on 18F-fluorocholine PET/CT in metastatic castration-resistant prostate cancer patients treated with abiraterone
por: De Giorgi, Ugo, et al.
Publicado: (2014)

New Prognostic Biomarkers in Metastatic Castration-Resistant Prostate Cancer
por: Conteduca, Vincenza, et al.
Publicado: (2021)

Grade group system and plasma androgen receptor status in the first line treatment for metastatic castration resistant prostate cancer
por: Cursano, M. C., et al.
Publicado: (2022)

Inflammatory Biomarkers as Predictors of Response to Immunotherapy in Urological Tumors
por: Schepisi, Giuseppe, et al.
Publicado: (2019)

Impact of Somatic DNA Repair Mutations on the Clinical Outcomes of Bone Metastases from Castration-Resistant Prostate Cancer
por: Cursano, Maria Concetta, et al.
Publicado: (2023)

Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer
por: Conteduca, Vincenza, et al.
Publicado: (2019)

Psychosocial Issues in Long-Term Survivors of Testicular Cancer
por: Schepisi, Giuseppe, et al.
Publicado: (2019)

Persistent Neutrophil to Lymphocyte Ratio >3 during Treatment with Enzalutamide and Clinical Outcome in Patients with Castration-Resistant Prostate Cancer
por: Conteduca, Vincenza, et al.
Publicado: (2016)

Prognostic Role of Systemic Inflammatory Indexes in Germ Cell Tumors Treated With High-Dose Chemotherapy
por: Cursano, Maria Concetta, et al.
Publicado: (2020)

CAR-T cell therapy: a potential new strategy against prostate cancer
por: Schepisi, Giuseppe, et al.
Publicado: (2019)

Systemic Immune-Inflammation Index Predicts the Clinical Outcome in Patients with mCRPC Treated with Abiraterone
por: Lolli, Cristian, et al.
Publicado: (2016)

Cell-free DNA as a diagnostic marker for cancer: current insights
por: Salvi, Samanta, et al.
Publicado: (2016)

Immunotherapy for Prostate Cancer: Where We Are Headed
por: Schepisi, Giuseppe, et al.
Publicado: (2017)

Immune System and DNA Repair Defects in Ovarian Cancer: Implications for Locoregional Approaches
por: Farolfi, Alberto, et al.
Publicado: (2019)

Endometrioid Cancer Associated With Endometriosis: From the Seed and Soil Theory to Clinical Practice
por: Farolfi, Alberto, et al.
Publicado: (2022)

Impact of the time interval between primary or interval surgery and adjuvant chemotherapy in ovarian cancer patients
por: Farolfi, Alberto, et al.
Publicado: (2023)

Androgen receptor gain in circulating free DNA and splicing variant 7 in exosomes predict clinical outcome in CRPC patients treated with abiraterone and enzalutamide
por: Del Re, M., et al.
Publicado: (2021)

(68)Ga-PSMA-11 PET/CT-Guided Stereotactic Body Radiation Therapy Retreatment in Prostate Cancer Patients with PSA Failure after Salvage Radiotherapy
por: Caroli, Paola, et al.
Publicado: (2020)

Vitamin D Deficiency in Testicular Cancer Survivors: A Systematic Review
por: Schepisi, Giuseppe, et al.
Publicado: (2021)

Immune Modulation in Prostate Cancer Patients Treated with Androgen Receptor (AR)-Targeted Therapy
por: Conteduca, Vincenza, et al.
Publicado: (2020)

Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib
por: Lolli, Cristian, et al.
Publicado: (2016)

Primary Mediastinal and Testicular Germ Cell Tumors in Adolescents and Adults: A Comparison of Genomic Alterations and Clinical Implications
por: Urbini, Milena, et al.
Publicado: (2021)

Vitiligo-like lesions in a patient treated with nivolumab for renal cell carcinoma
por: Lolli, Cristian, et al.
Publicado: (2018)

The New Frontier of Immunotherapy: Chimeric Antigen Receptor T (CAR-T) Cell and Macrophage (CAR-M) Therapy against Breast Cancer
por: Schepisi, Giuseppe, et al.
Publicado: (2023)

A Phase II Study of Everolimus Plus Oral Prednisone in Patients with Metastatic Renal Cell Cancer
por: Lolli, Cristian, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ferqclqqv2eugabpc1i7k47nlu